Brown A S, Wallack M K, Horstmann J T, Hamilton R W, Johnson J L, Rosato F E
Arch Surg. 1976 Sep;111(9):961-3. doi: 10.1001/archsurg.1976.01360270033005.
Because of their initial appearance on extremities, malignant melanomas lend themselves to isolated chemotherapeutic perfusions. Perfusion is attractive because one can deliver effective cytotoxic drugs without systemic toxicity. We are reviewing 20 patients treated between 1960 and 1973 with isolated perfusion. Melphalan (L-phenylalanine mustard) was the drug of choice. Eleven of the 20 patients had previous surgical treatment. Three of the 11 patients are still alive from 27 to 72 months postperfusion. Eight died after an average survival time of 33 months. Of the seven patients who underwent perfusion as primary therapy, four patients are alive from 25 to 76 months postperfusion, and three died after an average survival time of 34 months. There is direct correlation between stages and levels of melanoma, and perfusion and prolonged survival time.
由于恶性黑色素瘤最初出现在四肢，适合进行孤立性化疗灌注。灌注疗法具有吸引力，因为可以在不产生全身毒性的情况下给予有效的细胞毒性药物。我们正在回顾1960年至1973年间接受孤立性灌注治疗的20例患者。美法仑（L-苯丙氨酸氮芥）是首选药物。20例患者中有11例曾接受过手术治疗。这11例患者中有3例在灌注后27至72个月仍然存活。8例患者在平均存活33个月后死亡。在7例接受灌注作为主要治疗的患者中，4例在灌注后25至76个月仍然存活，3例在平均存活34个月后死亡。黑色素瘤的分期和分级与灌注及延长的生存时间之间存在直接关联。
